Robert A Figlin

Robert A Figlin

UNVERIFIED PROFILE

Are you Robert A Figlin?   Register this Author

Register author
Robert A Figlin

Robert A Figlin

Publications by authors named "Robert A Figlin"

Are you Robert A Figlin?   Register this Author

100Publications

2121Reads

42Profile Views

Gut microbiome, antibiotic use, and immunotherapy responsiveness in cancer.

Ann Transl Med 2019 Dec;7(Suppl 8):S309

Cedars-Sinai Medical Center, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2019.10.27DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6976491PMC
December 2019

Brain Metastases in Renal Cell Carcinoma: Immunotherapy Responsiveness Is Multifactorial and Heterogeneous.

J Clin Oncol 2019 Aug 20;37(23):1987-1989. Epub 2019 Jun 20.

1Cedars-Sinai Medical Center, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.00639DOI Listing
August 2019

Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma.

Clin Genitourin Cancer 2019 06 15;17(3):e454-e460. Epub 2019 Jan 15.

Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.01.004DOI Listing
June 2019

Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma.

Expert Rev Anticancer Ther 2019 03 4;19(3):259-271. Epub 2019 Feb 4.

a Department of Medicine, Division of Hematology and Oncology , Cedars-Sinai Medical Center , Los Angeles , CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2019.1573678DOI Listing
March 2019

Highlights in kidney cancer from the American Society of Clinical Oncology Genitourinary Cancers Symposium.

Authors:
Robert A Figlin

Clin Adv Hematol Oncol 2018 06;16(6):423-425

Cedars-Sinai Medical Center, Los Angeles, California.

View Article

Download full-text PDF

Source
June 2018

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.

J Clin Oncol 2018 03 19;36(9):867-874. Epub 2017 Dec 19.

Kevin D. Courtney and James Brugarolas, University of Texas Southwestern Medical Center; Naseem J. Zojwalla, Ann M. Lowe, Keshi Wang, Eli M. Wallace, and John A. Josey, Peloton Therapeutics, Dallas, TX; Jeffrey R. Infante, TN Oncology and Sarah Cannon Research Institute, Nashville, TN; Elaine T. Lam, University of Colorado Cancer Center, Aurora, CO; Robert A. Figlin, Cedars-Sinai Medical Center, Los Angeles, CA; Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Toni K. Choueiri, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.2627DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946714PMC
March 2018

Highlights in renal cell carcinoma from the Sixteenth International Kidney Cancer Symposium: commentary.

Authors:
Robert A Figlin

Clin Adv Hematol Oncol 2018 Jan;16 Suppl 1(1):21-23

Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California.

View Article

Download full-text PDF

Source
January 2018

Adjuvant Pazopanib Does Not PROTECT Against Recurrence of High-Risk, Initially Localized Renal Cell Cancer but Does Provide Novel Insights.

J Clin Oncol 2017 12 25;35(35):3895-3897. Epub 2017 Oct 25.

Grant D. Stewart, University of Cambridge, Cambridge, United Kingdom; Bradley C. Leibovich, Mayo Clinic, Rochester, MN; Sylvie Negrier, University of Lyon, Lyon, France; and Robert A. Figlin, Cedars-Sinai Medical Center, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.4242DOI Listing
December 2017

Targeted therapies for renal cell carcinoma.

Nat Rev Nephrol 2017 Aug 10;13(8):496-511. Epub 2017 Jul 10.

Urologic Oncology Program &Translational Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Department of Pharmacy Services, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrneph.2017.82DOI Listing
August 2017

Heterogeneity of Patients With Intermediate-Prognosis Metastatic Renal Cell Carcinoma Treated With Sunitinib.

Clin Genitourin Cancer 2017 04 18;15(2):291-299.e1. Epub 2016 Aug 18.

Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2016.08.013DOI Listing
April 2017

The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma.

Am Soc Clin Oncol Educ Book 2016 ;35:113-7

From the Texas A&M Health Science Center, Bryan TX; Baylor-Sammons Cancer Center, Dallas, TX; US Oncology, Texas Oncology, Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_158892DOI Listing
January 2017

Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.

Oncologist 2017 01 2;22(1):41-52. Epub 2016 Nov 2.

Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2016-0197DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5313263PMC
January 2017

Recent Advances in the Medical Treatment of Recurrent or Metastatic Renal Cell Cancer.

Drugs 2017 Jan;77(1):17-28

Urologic Oncology Program and Translational Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-016-0665-1DOI Listing
January 2017

Circulating tumor cells in prostate cancer: beyond enumeration.

Clin Adv Hematol Oncol 2017 Jan;15(1):63-73

Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.

View Article

Download full-text PDF

Source
January 2017

The value of surrogate endpoints for predicting real-world survival across five cancer types.

Curr Med Res Opin 2016 25;32(4):731-9. Epub 2016 Jan 25.

e Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California , Los Angeles , CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1185/03007995.2016.1140027DOI Listing
December 2016

Adjuvant treatment for renal cell carcinoma: do we finally have a major breakthrough?

Clin Adv Hematol Oncol 2016 Nov;14(11):907-914

Cedars-Sinai Medical Center, Los Angeles, California.

View Article

Download full-text PDF

Source
November 2016

Third-Line Treatment Options for Kidney Cancer.

Oncology (Williston Park) 2016 09;30(9):813-5

View Article

Download full-text PDF

Source
September 2016

Personalized Therapeutics and Value in Renal Cell Carcinoma: Moving Beyond Lines of Therapy.

J Oncol Pract 2016 05;12(5):424-5

Cedars-Sinai Medical Center, Los Angeles, CA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2016.012393DOI Listing
May 2016

Personalized immunotherapy ( AGS-003 ) when combined with sunitinib for the treatment of metastatic renal cell carcinoma.

Authors:
Robert A Figlin

Expert Opin Biol Ther 2015 30;15(8):1241-8. Epub 2015 Jun 30.

Cedars-Sinai Medical Center , 8700 Beverly Blvd, Los Angeles, CA , USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.2015.1063610DOI Listing
February 2016

Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?

Eur J Cancer 2016 Jan 15;53:96-104. Epub 2015 Dec 15.

GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.10.006DOI Listing
January 2016

A Rare Finding of a BRAF Mutation in Renal Cell Carcinoma with Response to BRAF-Directed Targeted Therapy.

Cureus 2016 Jan 6;8(1):e449. Epub 2016 Jan 6.

Oncology, Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.449DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744077PMC
January 2016

Literature Review and Profile of Cancer Diseases Among Afghan Refugees in Iran: Referrals in Six Years of Displacement.

Med Sci Monit 2015 Nov 23;21:3622-8. Epub 2015 Nov 23.

Division of Hematology/Oncology, Texas Tech University Health Sciences Center, El Paso, TX, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662241PMC
http://dx.doi.org/10.12659/msm.895173DOI Listing
November 2015

A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinoma.

Authors:
Robert A Figlin

Immunotherapy 2014 19;6(3):261-8. Epub 2013 Dec 19.

Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Saperstein Critical Care Tower 1S28, Los Angeles, CA 90048, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt.13.168DOI Listing
January 2015

Renal cell carcinoma: An update for the practicing urologist.

Asian J Urol 2015 Jan 16;2(1):19-25. Epub 2015 Apr 16.

Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22143882150003
Publisher Site
http://dx.doi.org/10.1016/j.ajur.2015.04.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730695PMC
January 2015

Ramucirumab in metastatic renal cell carcinoma: The beginning or the end?

Cancer 2014 Jun 27;120(11):1604-7. Epub 2014 Feb 27.

Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28636DOI Listing
June 2014

Kidney cancer: progress and controversies in neoadjuvant therapy.

Nat Rev Urol 2014 May 22;11(5):254-5. Epub 2014 Apr 22.

Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrurol.2014.89DOI Listing
May 2014

From the guest editor: renal cell carcinoma: the next decade of development.

Authors:
Robert A Figlin

Cancer J 2013 Jul-Aug;19(4):297-8

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0b013e3182a100fcDOI Listing
February 2014

A new age for vaccine therapy in renal cell carcinoma.

Cancer J 2013 Jul-Aug;19(4):365-70

Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0b013e31829d74b4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845885PMC
February 2014

Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions.

Clin Adv Hematol Oncol 2014 Feb;12(2):90-9

Cedars-Sinai Medical Center, Los Angeles, California.

View Article

Download full-text PDF

Source
February 2014

Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: a retrospective analysis.

Urol Oncol 2013 Nov 17;31(8):1826-31. Epub 2012 May 17.

Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2012.04.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3529212PMC
November 2013

Targeting angiogenesis in renal cell carcinoma.

Expert Opin Pharmacother 2013 Nov 28;14(16):2221-36. Epub 2013 Aug 28.

Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Urologic Oncology Program , 8700 Beverly Blvd, Los Angeles, CA 90048 , USA +1 310 423 7600 ; +1 310 659 3928 ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2013.832202DOI Listing
November 2013

Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors.

Int J Cancer 2013 Aug 12;133(4):788-96. Epub 2013 Feb 12.

Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA 90048, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ijc.28023
Publisher Site
http://dx.doi.org/10.1002/ijc.28023DOI Listing
August 2013

Understanding the role of MET kinase in cancer therapy.

J Clin Oncol 2013 Jan 3;31(2):169-70. Epub 2012 Dec 3.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.46.7738DOI Listing
January 2013

Tivozanib: current status and future directions in the treatment of solid tumors.

Expert Opin Investig Drugs 2012 Dec 26;21(12):1851-9. Epub 2012 Sep 26.

City of Hope Comprehensive Cancer Center, Department of Medical Oncology & Experimental Therapeutics, 1500 East Duarte Road, Duarte, CA 91010, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2012.733695DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934561PMC
December 2012

S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites.

Cancer Cell 2012 May;21(5):642-54

Department of Cancer Immunotherapeutics and Tumor Immunology, Beckman Research Institute and City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2012.03.039DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360884PMC
May 2012

Systemic therapy in renal cell carcinoma: advancing paradigms.

Oncology (Williston Park) 2012 Mar;26(3):290-301

View Article

Download full-text PDF

Source
March 2012

Systemic therapies for metastatic renal cell carcinoma in older adults.

Drugs Aging 2011 Aug;28(8):635-49

Division of Genitourinary Malignancies, Department of Medical Oncology Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.2165/11592880-000000
Web Search
http://link.springer.com/10.2165/11592880-000000000-00000
Publisher Site
http://dx.doi.org/10.2165/11592880-000000000-00000DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333645PMC
August 2011

Unraveling the role of hypoxia-inducible factor in renal cell carcinoma: a biological and therapeutic perspective.

Cancer Discov 2011 Aug;1(3):198-9

Division of Genitourinary Malignancies, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

View Article

Download full-text PDF

Source
http://cancerdiscovery.aacrjournals.org/cgi/doi/10.1158/2159
Publisher Site
http://dx.doi.org/10.1158/2159-8290.CD-11-0149DOI Listing
August 2011

STAT3: a target to enhance antitumor immune response.

Curr Top Microbiol Immunol 2011 ;344:41-59

Beckman Research Institute, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA 91010, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/82_2010_51DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3244828PMC
June 2011

Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma.

Target Oncol 2011 Mar 12;6(1):5-16. Epub 2011 Apr 12.

Division of Genitourinary Malignancies, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-011-0172-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253822PMC
March 2011

Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers.

Mol Cancer Ther 2010 Dec 15;9(12):3115-25. Epub 2010 Nov 15.

Division of Genitourinary Malignancies, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA 91010, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-10-0873DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3244352PMC
December 2010

Akt inhibitors in clinical development for the treatment of cancer.

Expert Opin Investig Drugs 2010 Nov 16;19(11):1355-66. Epub 2010 Sep 16.

City of Hope Comprehensive Cancer Center, Department of Medical Oncology & Experimental Therapeutics, 1500 East Duarte Road, Duarte, CA 91010, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2010.520701DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3244346PMC
November 2010

Deciphering the anticancer mechanisms of sunitinib.

Cancer Biol Ther 2010 Oct 1;10(7):712-4. Epub 2010 Oct 1.

Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.10.7.13130DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3093811PMC
October 2010

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.

Cancer 2010 Sep;116(18):4256-65

Department of Medicine, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25219DOI Listing
September 2010

Targeted therapies for non-small cell lung cancer: an evolving landscape.

Mol Cancer Ther 2010 Jul 22;9(7):1931-44. Epub 2010 Jun 22.

Division of Genitourinary Malignancies, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-10-0239DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3244351PMC
July 2010

Targeted therapies for renal cell carcinoma: understanding their impact on survival.

Target Oncol 2010 Jun 15;5(2):131-8. Epub 2010 Jul 15.

Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11523-010-0145-6
Publisher Site
http://dx.doi.org/10.1007/s11523-010-0145-6DOI Listing
June 2010

Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors.

Clin Med Insights Oncol 2010 Jun 9;4:43-53. Epub 2010 Jun 9.

Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2902205PMC
http://dx.doi.org/10.4137/cmo.s1590DOI Listing
June 2010

Renal cell carcinoma therapy in 2010: many options with little comparative data.

Clin Adv Hematol Oncol 2010 Mar;8(3):191-200

Division of Genitourinary Malignancies, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California 91010, USA.

View Article

Download full-text PDF

Source
March 2010

Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma.

J Clin Oncol 2010 Jan 14;28(3):475-80. Epub 2009 Dec 14.

Baylor-Sammons/Texas Oncology Physician's Association, Dallas, TX 75246, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.21.6994DOI Listing
January 2010

Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors.

J Urol 2009 Dec;182(6):2569-77

Medical Oncology and Laboratory of Pre-Clinical Oncology and Developmental Therapeutics, Istituto Di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2009.08.085DOI Listing
December 2009

Anti-angiogenic therapy in renal cell carcinoma: Alone, in combination, or sequentially.

Authors:
Robert A Figlin

Clin Adv Hematol Oncol 2009 Oct;7(10):662-5

City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

View Article

Download full-text PDF

Source
October 2009

Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.

Cancer 2009 Aug;115(16):3618-30

Juravinski Cancer Center, McMaster University, Hamilton, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.24409DOI Listing
August 2009

Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies.

Med Oncol 2009 20;26(2):202-9. Epub 2009 Feb 20.

Montefiore Medical Center-North Division/New York Medical College, 600 East 233rd Street, Bronx, NY, 10466, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12032-009-9177-0DOI Listing
July 2009

CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer.

BMC Cancer 2009 Jun 29;9:213. Epub 2009 Jun 29.

Department of Medical Oncology & Therapeutics Research, City of Hope and Beckman Research Institute, Duarte, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-9-213DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2708193PMC
June 2009

Novel therapeutics for metastatic renal cell carcinoma.

Cancer 2009 May;115(10 Suppl):2361-7

Genitourinary Oncology Program, Baylor Sammons Cancer Center, Dallas, Texas, USA.

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.24235
Publisher Site
http://dx.doi.org/10.1002/cncr.24235DOI Listing
May 2009

Experimental therapy for advanced renal cell carcinoma.

Expert Opin Investig Drugs 2008 Nov;17(11):1693-702

Baylor Sammons Cancer Center, Genitourinary Oncology Program, Texas Oncology, PA, Dallas, Texas 75246, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.17.11.1693DOI Listing
November 2008

The role of targeting mammalian target of rapamycin in lung cancer.

Clin Lung Cancer 2008 Nov;9(6):340-5

Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304117023
Publisher Site
http://dx.doi.org/10.3816/CLC.2008.n.049DOI Listing
November 2008

Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.

Authors:
Robert A Figlin

Nat Clin Pract Oncol 2008 Oct 8;5(10):601-9. Epub 2008 Jul 8.

Division of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Care Center, Duarte, CA 91010, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncponc1173DOI Listing
October 2008

Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma.

Cancer 2008 Oct;113(7):1552-8

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.23776DOI Listing
October 2008

Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.

Oncologist 2008 Oct 6;13(10):1084-96. Epub 2008 Oct 6.

Baylor University Medical Center, Sammons Cancer Center, Dallas, Texas 75246, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2008-0120DOI Listing
October 2008

Bevacizumab plus interferon alpha in patients with metastatic renal cell carcinoma.

Nat Clin Pract Oncol 2008 Aug 17;5(8):436-7. Epub 2008 Jun 17.

Division of Medical Oncology and Experimental Therapeutics, City of Hope Cancer Center, Duarte, CA 91010, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncponc1162DOI Listing
August 2008